Table 2

Significant predictors of sustained remission over 3 years of adalimumab treatment

Predictor, OR (95% CI)Sustained ASDAS IDSustained PSpARC remission
Full modelReduced modelFull modelReduced model
Baseline demographic and disease characteristics
 Normal hs-CRP (no vs yes)NS0.18 (0.06 to 0.52)NSNS
 EnthesitisNSNS0.79 (0.68 to 0.93)0.85 (0.77 to 0.95)
 Prior DMARDs (yes vs no)NSNS0.20 (0.05 to 0.74)0.22 (0.07 to 0.66)
 BASDAINS0.57 (0.41 to 0.78)NS0.70 (0.50 to 0.97)
 BMINSNSNS0.88 (0.77 to 0.99)
Treatment response (yes vs no)
 ASDAS MI at week 128.19 (1.08 to 61.91)NSNSNS
 ASDAS ID at week 12NS8.01 (2.47 to 25.97)NSNS
 PSpARC remission at week 12NSNS13.05 (1.75 to 97.52)20.27 (5.37 to 76.46)
  • ASDAS, Ankylosing Spondylitis Disease Activity Score; ASDAS ID, ASDAS inactive disease; ASDAS MI, ASDAS major improvement (Δ ≥2.0); BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; DMARD, disease-modifying antirheumatic drug; hs-CRP, high-sensitivity C-reactive protein; NS, not significant; PSpARC, Peripheral SpondyloArthritis Response Criteria.